Literature DB >> 26238858

Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics.

E A Marcus1,2, G Sachs2,3,4, D R Scott2,3.   

Abstract

BACKGROUND: Successful eradication of Helicobacter pylori is becoming more difficult, mainly due to emerging antibiotic resistance. Treatment regimens containing bismuth have increased efficacy, but the mechanism is unknown. Helicobacter pylori is a neutralophile adapted to survive the acidic gastric environment via acid acclimation, but demonstrates more robust growth at neutral pH. Many antibiotics used to treat H. pylori rely on bacterial growth. AIM: To investigate the mechanism of increased efficacy of bismuth-containing H. pylori treatment regimens.
METHODS: RNAseq and qPCR, urease activity in permeabilised and intact bacteria, internal pH and membrane potential were measured with and without colloidal bismuth subcitrate (CBS). Bacterial survival was assessed with CBS and/or ampicillin.
RESULTS: Genes involved with metabolism and growth were upregulated in the presence of CBS at acidic pH. Urease activity of permeabilised H. pylori at pH 7.4 and 4.5 decreased in the presence of CBS, but intact urease activity decreased only at acidic pH. The fall in cytoplasmic pH with external acidification was diminished by CBS. The increase in membrane potential in response to urea addition at acidic medium pH was unaffected by CBS. The impact of CBS and ampicillin on H. pylori survival was greater than either agent alone.
CONCLUSIONS: Bismuth is not acting directly on urease or the urea channel. Colloidal bismuth subcitrate impedes proton entry into the bacteria, leading to a decrease in the expected fall in cytoplasmic pH. With cytoplasmic pH remaining within range for increased metabolic activity of a neutralophile, the efficacy of growth-dependent antibiotics is augmented.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26238858      PMCID: PMC4558396          DOI: 10.1111/apt.13346

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  56 in total

Review 1.  The actions of bismuth in the treatment of Helicobacter pylori infection.

Authors:  J R Lambert; P Midolo
Journal:  Aliment Pharmacol Ther       Date:  1997-04       Impact factor: 8.171

2.  Interactions among the seven Helicobacter pylori proteins encoded by the urease gene cluster.

Authors:  Petra Voland; David L Weeks; Elizabeth A Marcus; Christian Prinz; George Sachs; David Scott
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-09-04       Impact factor: 4.052

3.  Gene expression in vivo shows that Helicobacter pylori colonizes an acidic niche on the gastric surface.

Authors:  David R Scott; Elizabeth A Marcus; Yi Wen; Jane Oh; George Sachs
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-16       Impact factor: 11.205

4.  Role of Hpn and NixA of Helicobacter pylori in susceptibility and resistance to bismuth and other metal ions.

Authors:  H L Mobley; R M Garner; G R Chippendale; J V Gilbert; A V Kane; A G Plaut
Journal:  Helicobacter       Date:  1999-09       Impact factor: 5.753

5.  The role of internal urease in acid resistance of Helicobacter pylori.

Authors:  D R Scott; D Weeks; C Hong; S Postius; K Melchers; G Sachs
Journal:  Gastroenterology       Date:  1998-01       Impact factor: 22.682

Review 6.  The actions of bismuth in the treatment of Helicobacter pylori infections: an update.

Authors:  Ruiguang Ge; Zhuo Chen; Qinglu Zhou
Journal:  Metallomics       Date:  2012-02-23       Impact factor: 4.526

7.  The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin.

Authors:  E A Marcus; N Inatomi; G T Nagami; G Sachs; D R Scott
Journal:  Aliment Pharmacol Ther       Date:  2012-09-25       Impact factor: 8.171

Review 8.  Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.

Authors:  Jay Luther; Peter D R Higgins; Phillip S Schoenfeld; Paul Moayyedi; Nimish Vakil; William D Chey
Journal:  Am J Gastroenterol       Date:  2009-09-15       Impact factor: 10.864

9.  Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy.

Authors:  Mitsushige Sugimoto; Takahisa Furuta; Naohito Shirai; Chise Kodaira; Masafumi Nishino; Mutsuhiro Ikuma; Takashi Ishizaki; Akira Hishida
Journal:  Helicobacter       Date:  2007-08       Impact factor: 5.753

10.  A proteomic approach for the identification of bismuth-binding proteins in Helicobacter pylori.

Authors:  Ruiguang Ge; Xuesong Sun; Qing Gu; Rory M Watt; Julian A Tanner; Benjamin Chun Yu Wong; Harry Huaxiang Xia; Jian-Dong Huang; Qing-Yu He; Hongzhe Sun
Journal:  J Biol Inorg Chem       Date:  2007-05-15       Impact factor: 3.358

View more
  8 in total

1.  Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection.

Authors:  Chang Seok Bang; Hyun Lim; Hae Min Jeong; Woon Geon Shin; Jae Ho Choi; Jae Seung Soh; Ho Suk Kang; Young Joo Yang; Ji Taek Hong; Suk Pyo Shin; Ki Tae Suk; Jae Jun Lee; Gwang Ho Baik; Dong Joon Kim
Journal:  Gut Microbes       Date:  2020-05-02

Review 2.  Eradication of Helicobacter pylori Infection.

Authors:  Elizabeth A Marcus; George Sachs; David R Scott
Journal:  Curr Gastroenterol Rep       Date:  2016-07

3.  Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.

Authors:  Wei Fu; Zhiqiang Song; Liya Zhou; Yan Xue; Yu Ding; Baojun Suo; Xueli Tian; Li Wang
Journal:  Dig Dis Sci       Date:  2017-04-08       Impact factor: 3.199

4.  Multi-omics and temporal dynamics profiling reveal disruption of central metabolism in Helicobacter pylori on bismuth treatment.

Authors:  Bingjie Han; Zhen Zhang; Yanxuan Xie; Xuqiao Hu; Haibo Wang; Wei Xia; Yulan Wang; Hongyan Li; Yuchuan Wang; Hongzhe Sun
Journal:  Chem Sci       Date:  2018-07-25       Impact factor: 9.825

5.  Action of Colloidal Bismuth Hydroxide Gel and its Commercial Cream on Enteropathogens and Colonizers of the Gastrointestinal Tract.

Authors:  Tomás Subils; Cecilia Casabonne; Agustina González; Virginia Aquili; Claudia E Balagué
Journal:  J Glob Infect Dis       Date:  2018 Oct-Dec

Review 6.  High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection - A review of the strengths, weaknesses, and proposed solutions.

Authors:  Chi-Tan Hu
Journal:  Tzu Chi Med J       Date:  2021-11-15

7.  Facile Synthesis of Zn-Doped Bi2O3 Nanoparticles and Their Selective Cytotoxicity toward Cancer Cells.

Authors:  Maqusood Ahamed; Mohd Javed Akhtar; M A Majeed Khan; ZabnAllah M Alaizeri; Hisham Alhadlaq
Journal:  ACS Omega       Date:  2021-06-29

8.  Efficacy and Safety of Wei Bi Mei, a Chinese Herb Compound, as an Alternative to Bismuth for Eradication of Helicobacter pylori.

Authors:  Lei Li; FanDong Meng; Shengtao Zhu; ShuiLong Guo; YongJun Wang; Xin Zhao; YiLin Sun; Yan Zhang; QinQin Wang; HuFeng Xu; ShuTian Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2018-02-05       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.